CD274 and neoplasm: Overall, 89 patients (53.3%, Supplementary Table 3), with either PD-L1 positivity in tumour cells or high level of PD-L1 in TILs, could be considered as potential responders to anti-PD-1/PD-L1 blocking agents after considering evidence from previous clinical trials in other malignancies10–12.